Simulation contact lenses for AMD health state utility values in NICE appraisals: a different reality

BACKGROUND/AIMS: The National Institute for Health and Care Excellence (NICE) has recommended the use of ranibizumab for neovascular age-related macular degeneration (AMD) and for diabetic macular oedema (DMO) as part of its health technology appraisal process. In the economic evaluations of both in...

Descripción completa

Detalles Bibliográficos
Autores principales: Butt, Thomas, Crossland, Michael D, West, Peter, Orr, Shepley W, Rubin, Gary S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392203/
https://www.ncbi.nlm.nih.gov/pubmed/25351679
http://dx.doi.org/10.1136/bjophthalmol-2014-305802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392203/
https://www.ncbi.nlm.nih.gov/pubmed/25351679
http://dx.doi.org/10.1136/bjophthalmol-2014-305802

Ejemplares similares